Does CDKN2A loss predict palbociclib benefit?

Current Oncology

Volumn 22, Issue 6, 2015, Pages e498-e501

  Gao, J ^a   Adams, R P ^b   Swain, Sandra M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Medical oncology

Indexed keywords

ALPHA TOCOPHEROL; ANASTROZOLE; CAPECITABINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; GAMMA UROGASTRONE; LETROZOLE; PALBOCICLIB; PENTOXIFYLLINE; PROGESTERONE RECEPTOR;

AGED; ARTICLE; CASE REPORT; CDKN2A GENE; DISEASE COURSE; DRUG DOSE REDUCTION; EXCISION; FEBRILE NEUTROPENIA; FEMALE; GENE; GENE LOSS; HORNER SYNDROME; HUMAN; HYPERBARIC OXYGEN; INTRADUCTAL CARCINOMA; LYMPHEDEMA; MASTECTOMY; MELANOMA; PTOSIS;

EID: 84951806875     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2700     Document Type: Article

References (13)

1. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, her2-negative, advanced breast cancer (paloma-1/trio-18): a randomized phase 2 study. Lancet Oncol 2015;16:25-35.
2. Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor- positive advanced breast cancer. N Engl J Med 2015;373:209-19.
3. Johnson SM, Torrice CD, Bell JF, et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by cdk4/6 inhibition. J Clin Invest 2010;120:2528-36.
4. Yu Q, Sicinska E, Geng Y, et al. Requirement for cdk4 kinase function in breast cancer. Cancer Cell 2006;9:23-32.
5. Scheicher R, Hoelbl-Kovacic A, Bellutti F, et al. cdk6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 2015;125:90-101.
6. Gong X, Chiou LC, Lallena M, et al. Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of cdk4 and cdk6 [abstract 3104]. Cancer Res 2015;75:3104.
7. Patnaik A, Rosen LS, Tolaney SM, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for cdk4 and cdk6, in patients with metastatic breast cancer [abstract CT232]. Cancer Res 2014;74:.
8. Rader J, Russell MR, Hart LS, et al. Dual cdk4/cdk6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 2013;19:6173-82.
9. Shan M, Zhang X, Liu X, et al. p16 and p53 play distinct roles in different subtypes of breast cancer. PLoS One 2013;8:e76408.
10. Lee JJ, Ko E, Cho J, et al. Methylation and immunoexpression of p16(INK4a) tumor suppressor gene in primary breast cancer tissue and their quantitative p16(INK4a) hypermethylation in plasma by real-time pcr. Korean J Pathol 2012;46:554-61.
11. Bogina GS, Lunardi G, Marcolini L et al. p16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas. Mod Pathol 2014;27:204-13.
12. Peurala E, Koivunen P, Haaspasaari KM, Bloigu R, Jukkola- Vuorinen A. The prognostic significance and value of cyclin D1, cdk4 and p16 in human breast cancer. Breast Cancer Res 2013;15:R5.
13. Finn R, Dering J, Conklin D, et al. PD0332991, a selective cycl in D kinase 4/6 inhibitor, preferent ial ly inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.